www.fdanews.com/articles/144999-fda-grants-lexicon-orphan-drug-designation-for-telotristat-etiprate-for-the-treatment-of-carcinoid-syndrome
FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
March 21, 2012
Lexicon Pharmaceuticals announced that the U.S. Food and Drug Administration has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.
Bradenton Herald
Bradenton Herald